从最新的指南看糖尿病黄斑水肿的治疗策略和方案  

Treatment strategy and plan for diabetic macular edema based on the latest guidelines

作　　者：卢颖毅[1] 戴虹[1] Lu Yingyi;Dai Hong(Beijing Hospital,National Center of Gerontology,Beijing100730,China)

机构地区：[1]北京医院国家老年医学中心,100730

出　　处：《中华实验眼科杂志》2018年第6期401-403,共3页Chinese Journal Of Experimental Ophthalmology

基　　金：北京市自然科学基金项目（7152123）;首都特色临床研究项目（Z151100004015147）

摘　　要：糖尿病黄斑水肿（DME）是引起视力下降的常见原因。随着新的治疗方法的应用，DME的治疗理念也发生了变化，以提高患者视功能为目的的治疗方案已成为主流。近期国际上发布的DME指南介绍了DME的最新研究结果，提出了基于循证医学证据的临床建议和临床路径。抗血管内皮生长因子（VEGF）适合昕有类型的DME一线治疗，激光光凝、眼内糖皮质激素注射除在某些特定情况下可替代抗VEGF作为首选治疗外，多作为抗VEGF治疗的补充、协同。理解和遵循相关指南可为DME的诊疗行为提供规范和指导。Diabetic macular edema （DME） is a common reason fir vision decrease. The concept of DME treatment regime has been changed to increase the vision-sight of patients since the onset of new treatment. Recent DME guidelines introduced the latest researches of DME, which raised new clinical suggestion and clinical pathway based on evidence-based medicine. Anti-vascular endothelial growth tactor （VEGF） treatment is the first-line therapy for all types of DME,laser photocoagulation and intravitreal steroid injection are often the supplementary treatment except for some special cases in which they can be the substitution for anti-VEGF treatment. The regime for DME treatment now is combination. To understand and follow the guidelines can help us instruct and standardize our management on DME.

关 键 词：糖尿病黄斑水肿/治疗 抗血管内皮生长因子 激光光凝 眼内糖皮质激素 

分 类 号：R587.2[医药卫生—内分泌] R774.5[医药卫生—内科学]